Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia

Abstract

DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: a systematic review

“…Relationships between thermal dose parameters and clinical outcome have not only been found in recurrent breast cancer, but also in cervical carcinomas [21,22,64], sarcomas [56,65], rectal cancer [66], brain tumors [67] and melanomas [2,68]. Thermal dose variables (maximum CEM43, CEM43T50, CEM43T90, CEM43T100, and TRISE) [2,21,22,56,64,65], minimum temperature variables (minimum temperature, T90) [65,67,69] and maximum temperature variables [2] were found to relate to outcome.…”

“…The most commonly used thermal isoeffective dose is the number of equivalent minutes at 43 C (CEM43) [19,20]. Other parameters representing minimum or median tumor temperature levels achieved during HT, include T90, T50, and TRISE [21][22][23].…”

Radiosensitization by Hyperthermia: The Effects of Temperature, Sequence, and Time Interval in Cervical Cell Lines

“…Mild hyperthermia (i.e., heating the tumor to 40-42.5 • C for 1 h) has been used in the clinic to sensitize radiotherapy since the 1980s, with excellent results for various tumor types [2,3], including cervical cancer [4][5][6]. Radiotherapy plus hyperthermia is a good alternative for women with contraindications for chemotherapy, usually because of limited renal function or frailty, as the survival after daily radiotherapy plus weekly hyperthermia is similar to that of chemoradiotherapy in cervical cancer [7,8].…”

Dedicated 70 MHz RF systems for hyperthermia of challenging tumor locations

“…Clinical results are very good, and adding hyperthermia typically yields an increase in tumor response on the order of 15-20% [3,4]. Realizing a sufficiently high tumor temperature is important as treatment outcome is correlated with the achieved tumor temperature [5][6][7][8]. Hyperthermia is tumor-selective if given sequentially, shortly before or after radiotherapy.…”

“…This is very important in view of the strong dose-effect relationship found for many tumors, e.g. as found in a recent review for recurrent breast cancer treated mainly with 434 MHz applicators [8] and for cervical tumors treated with phased array systems of RF antennas in Rotterdam [6,7] and in Amsterdam [36]. The next step is to promote more wide clinical use of these solutions for challenging locations.…”